BridgeBio Pharma (BBIO) Total Debt (2018 - 2026)

BridgeBio Pharma has disclosed Total Debt across 9 years of filings, most recently posting $1.3 billion for Q1 2026.

• Total Debt for Q1 2026 came in at $1.3 billion, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $1.3 billion (changed N/A YoY), and the FY2025 annual result was $564.6 million, up 3.56% from the prior year.
• Total Debt came in at $1.3 billion for Q1 2026 at BridgeBio Pharma, up from $564.6 million in the prior quarter.
• In the past five years, Total Debt ranged from a high of $1.3 billion in Q1 2026 to a low of $418.4 million in Q2 2022.
• The 5-year median for Total Debt is $436.2 million (2024), against an average of $527.7 million.
• Across the five-year window, Total Debt jumped 359.83% in 2022 and dropped 1.25% in 2024, its largest moves.
• BridgeBio Pharma's Total Debt stood at $431.0 million in 2022, then gained by 3.59% to $446.4 million in 2023, then grew by 22.11% to $545.2 million in 2024, then gained by 3.56% to $564.6 million in 2025, then surged by 128.3% to $1.3 billion in 2026.
• The last three Total Debt figures came in at $1.3 billion (Q1 2026), $564.6 million (Q4 2025), and $740.4 million (Q3 2025), per Business Quant data.